154 related articles for article (PubMed ID: 12670369)
1. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Ballow M; Berger M; Bonilla FA; Buckley RH; Cunningham-Rundles CH; Fireman P; Kaliner M; Ochs HD; Skoda-Smith S; Sweetser MT; Taki H; Lathia C
Vox Sang; 2003 Apr; 84(3):202-10. PubMed ID: 12670369
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
4. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
Lebing W; Remington KM; Schreiner C; Paul HI
Vox Sang; 2003 Apr; 84(3):193-201. PubMed ID: 12670368
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
6. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
7. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.
Mahadevia PJ; Strell J; Kunaprayoon D; Gelfand E
Value Health; 2005; 8(4):488-94. PubMed ID: 16091026
[TBL] [Abstract][Full Text] [Related]
8. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
9. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
[TBL] [Abstract][Full Text] [Related]
10. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
Mahadevia PJ
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
[TBL] [Abstract][Full Text] [Related]
12. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
Shah SR
Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.
Church JA; Leibl H; Stein MR; Melamed IR; Rubinstein A; Schneider LC; Wasserman RL; Pavlova BG; Birthistle K; Mancini M; Fritsch S; Patrone L; Moore-Perry K; Ehrlich HJ;
J Clin Immunol; 2006 Jul; 26(4):388-95. PubMed ID: 16705486
[TBL] [Abstract][Full Text] [Related]
14. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
Pirofsky B
Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
[TBL] [Abstract][Full Text] [Related]
15. The product: All intravenous immunoglobulins are not equivalent.
Siegel J
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):78S-84S. PubMed ID: 16229678
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
17. Safety and patient acceptability of intravenous immune globulin in 10% maltose.
Ochs HD; Buckley RH; Pirofsky B; Fischer SH; Rousell RH; Anderson CJ; Wedgwood RJ
Lancet; 1980 Nov; 2(8205):1158-9. PubMed ID: 6107768
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intravenous immunoglobulin: a systematic review.
Koleba T; Ensom MH
Pharmacotherapy; 2006 Jun; 26(6):813-27. PubMed ID: 16716135
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients.
Gelfand EW; Hanna K;
J Clin Immunol; 2006 May; 26(3):284-90. PubMed ID: 16783467
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes.
Alyanakian MA; Bernatowska E; Scherrmann JM; Aucouturier P; Poplavsky JL
Vox Sang; 2003 Apr; 84(3):188-92. PubMed ID: 12670367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
